Walleye Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-699,621
| Closed | -$3.63M | – | 2814 |
|
|
2024
Q3 | $3.63M | Buy |
699,621
+88,829
| +15% | +$461K | 0.01% | 534 |
|
|
2024
Q2 | $1.57M | Sell |
610,792
-11,334
| -2% | -$29.1K | ﹤0.01% | 913 |
|
|
2024
Q1 | $3.06M | Sell |
622,126
-305,688
| -33% | -$1.5M | 0.01% | 619 |
|
|
2023
Q4 | $8.16M | Buy |
927,814
+622,022
| +203% | +$5.47M | 0.02% | 243 |
|
|
2023
Q3 | $3.51M | Buy |
305,792
+192,004
| +169% | +$2.2M | 0.01% | 479 |
|
|
2023
Q2 | $2.88M | Sell |
113,788
-166,574
| -59% | -$4.22M | 0.01% | 411 |
|
|
2023
Q1 | $9.03M | Sell |
280,362
-228,333
| -45% | -$7.35M | 0.14% | 155 |
|
|
2022
Q4 | $9.39M | Sell |
508,695
-14,350
| -3% | -$265K | 0.17% | 129 |
|
|
2022
Q3 | $14.1M | Buy |
523,045
+58,075
| +12% | +$1.57M | 0.27% | 56 |
|
|
2022
Q2 | $6.43M | Sell |
464,970
-40,731
| -8% | -$563K | 0.18% | 128 |
|
|
2022
Q1 | $9.86M | Buy |
505,701
+148,464
| +42% | +$2.89M | 0.26% | 74 |
|
|
2021
Q4 | $5.83M | Buy |
357,237
+302,760
| +556% | +$4.94M | 0.18% | 114 |
|
|
2021
Q3 | $1.52K | Sell |
54,477
-52,382
| -49% | -$1.46K | 0.04% | 285 |
|
|
2021
Q2 | $3.17K | Buy |
106,859
+36,610
| +52% | +$1.09K | 0.11% | 147 |
|
|
2021
Q1 | $1.96K | Sell |
70,249
-1,116
| -2% | -$31 | 0.11% | 140 |
|
|
2020
Q4 | $2.02K | Buy |
+71,365
| New | +$2.02K | 0.14% | 114 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 1069 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 965 |
|
|
2018
Q3 | $438K | Buy |
+17,644
| New | +$438K | 0.2% | 130 |
|